Interim report January-September 2014 July-September 2014

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Interim report January-September 2014

July-September 2014 · Net sales amounted to SEK 508 million (505), an increase of 0.5% compared to same quarter last year (-3.2% in fixed FX-rates) · EBITDA decreased by 24.4% compared to same quarter last year and amounted to SEK 51 million (68) · Operating profit (EBIT) amounted to SEK 25 million (44), giving an operating margin of 5.0% (8.6) · Profit after tax amounted to SEK 8 million (27), giving a net margin of 1.6% (5.4) · Earnings per share amounted to SEK 0.22 (1.07), after dilution SEK 0.22 kr (1.03) January-September 2014 · Net sales amounted to SEK 1 696 million (1 552), an increase of 9.3% compared to same period last year (6.3% in fixed FX rates) · EBITDA increased by 24.2% compared to same period last year and amounted to SEK 252 million (203) · Operating profit (EBIT) amounted to SEK 177 million (134), giving an operating margin of 10.4% (8.6) · Profit after tax amounted to SEK 111 million (83), giving a net margin of 6.5% (5.3) · Earnings per share amounted to SEK 3.37 (3.26), after dilution SEK 3.37 (3.11) · Cash flow from operating activities was SEK 168 million (83) · Net debt to Equity was -0.3 (0.7) Key figures Jul - Change      Change Oct 13 FY Sep Jan - Sep SEK million 2014 2013 in % 2014 2013 in % -Sep 14 2013 Net sales 507,6 504,8 0,5 1 696,4 1 551, 9,3 2 269,2 2 124, 8 6 Net sales 488,7 -3,2 1 649,0 6,3 (constant FX rates) EBITDA 51,1 67,6 -24,4 251,9 202,8 24,2 332,1 283,0 EBIT 25,3 43,6 -42,0 176,8 133,6 32,3 231,3 188,1 EBIT margin (%) 5,0 8,6 10,4 8,6 10,9 8,9 Earnings per 0,22 1,07 3,37 3,26 3,81 3,72 share Non-recurring 0,0 0,1 0,0 2,3 4,2 6,5 items Return on 10,8 26,1 10,8 14,5 equity (%) Return on 19,4 15,4 19,4 17,2 operating capital (%) Equity to 59,5 18,6 59,5 37,6 assets (%) Net debt -412,6 443,5 -412,6 409,8 Net debt to -0,3 0,7 -0,3 0,6 Equity Net debt to -1,2 1,7 -1,2 1,4 EBITDA Thomas Eldered, CEO: “Overall, Recipharm’s business was relatively stable in the third quarter. Sales continued at a high level, operating profit was affected by certain one-time and phasing effects and operating cash flow was much stronger than the previous year. Sales were the highest for a third quarter ever, benefitting from favourable currency effects and solid activity and demand in most operating companies. Sales in Development & Technology continued to increase, although as expected at a slower pace than earlier in the year. Technical issues, supply shortage of some components as well as effects from the discontinued French distribution business, offset this. These issues together with phasing effects from the previous two quarters contributed to a lower than planned manufacturing output impacting our results. Throughout the quarter we also had unusually high corporate activity from evaluating acquisition opportunities including due diligences, resulting in increased external costs. Operating cash flow for the quarter, at over SEK 75 million (last year SEK 23 million), was strong as working capital was reduced. The acquisition of the Italian Corvette Pharmaceutical Services Group, from the 1st of October, provides access to highly interesting markets including Italy and a number of emerging markets, many of which are new to Recipharm. It increases our capacity and capability in lyophilisation and Corvette will significantly contribute to Recipharm’s intellectual property backed business. We will continue to develop Recipharm towards our long-term objectives and in line with our strategic growth agenda, by a combination of investing in our current business and further acquisitions and long-term partnerships, like the recently announced collaboration with Isofol Medical. The new SEK 1 500 million credit facility combined with the authorisation for the Board to issue new shares in relation to acquisitions further strengthen the capability to grow the business in this direction”. The full interim report is attached through the link at the end of the press release. This information is published in accordance with the Swedish Securities Market Act, the Swedish Financial Instruments Trading Act and/or the regulations of NASDAQ Stockholm. This information was subitted for publication on 7 November 2014, at 07:45 am CET. Recipharm  invites investors, analysts and media to a telephone conference together with a web presentation (in English) on November 7 at 10:00 CET where CEO Thomas Eldered and CFO Björn Westberg will present and comment on the interim report and answer questions. To participate in the conference please dial: From Sweden, tel: +46 8 506 443 86 From Denmark, tel: +45 32 71 42 62 From Finland, tel: +358 9 8171 0375 From Norway, tel: +47 21 06 61 13 From the UK, tel: +44 20 7153 9154 From Germany, tel: +49 69 2017 44 210 From France, tel: +33 1 70 70 95 02 From Spain, tel: +34 914 142 009 From Switzerland, tel: +41 44 580 65 22 From the US, tel:+1 877 423 0830 From Italy, tel: + +39 02 3600 6663 Pin code for participants: 942621# To access the presentation during the conference use the following link: http://event.onlineseminarsolutions.com/r.htm...8595AA605A 9 D778C06DA2DA For more information, please visit www.recipharm.com or contact: Thomas Eldered, VD, thomas.eldered@recipharm.com, tel: +46 8 602 52 00 Björn Westberg, CFO, bjorn.westberg@recipharm.com, tel: +46 8 602 46 20 About Recipharm Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry based in Sweden employing some 1,750 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures more than 250 different products to customers ranging from Big Pharma through to smaller research- and development companies. Recipharm’s turnover is approximately SEK 2.6 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany, Spain and Italy and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq OMX Stockholm. For more information on Recipharm and our services, please visit www.recipharm.com. Recipharm AB (publ) Corporate identity number 556498-8425 Address Lagervägen 7, SE-136 50 Jordbro Telephone 46 8 602 52 00 Fax 46 8 81 87 03, www.recipharm.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Wealth Forum Puts AI and Tokenisation Before Private Wealth

Updated Category News Views 63

Private wealth is about to get squeezed from three directions at once: younger heirs, smarter machines and assets that do not fit neatly in the old family-office binder. That is the real backdrop to the Future of Wealth Forum, a new GFTN and Luxembourg House of Financial Technology partnership slated for Luxembourg City on September 27-29, 2027. It is early days,...

Continue Reading
Ridgeline’s Dome Roof Award Signals Durable Craft Demand

Updated Category News Views 36

A faceted dome in the Alabama woods is about as far from a cookie-cutter reroof as it gets. Ridgeline Roofing & Restoration’s 2026 Excellence Award from Brava Roof Tile matters because the job in Pell City demanded the sort of painstaking field execution that separates a capable contractor from a crew merely moving shingles fast. Geometry Is Where Easy Claims Go to Die...

Continue Reading
Marina del Rey's Travel Award Brings Fresh Attention

Updated Category News Views 12

A harbor town just got handed a useful little megaphone. On November 18, 2026, the Marina del Rey Tourism Board said Marina del Rey had been selected as a winner in Good Housekeeping's 2027 Travel Awards. That is not a quarterly earnings event, and nobody ought to dress it up as one. Still, in the visitor economy, recognition from a broad consumer publication can matter...

Continue Reading
Clarivate's 2026 Research List Carries a Trust Test

Updated Category News Views 209

Seven thousand ninety awards can look like a victory lap until you remember how easily raw citation counts can be gamed. Clarivate’s 2026 Highly Cited Researchers list is more interesting for its insistence on screening than for the familiar names at the top. In a research world where publication volume, self-citation and paper mills have made plenty of people...

Continue Reading
Kendra Scott’s Dolly Tribute Tests Purposeful Luxury

Updated Category News Views 25

Butterflies, music notes, and a $70 pendant are carrying a surprisingly serious brand message this November. Kendra Scott’s new Dolly Parton Tribute Collection is plainly built to celebrate Dolly’s style, but it also shows how a consumer brand can make sentiment do some commercial heavy lifting without turning the whole thing into mush. The collection arrived November...

Continue Reading
Lotte's Songdo Plant 1 Puts 120,000 Liters on Deck

Updated Category News Views 95

A 120,000-liter biomanufacturing plant is not a ribbon-cutting trinket; it is a serious industrial bet that has to earn its keep one qualified batch at a time. LOTTE Biologics has completed Plant 1 at its Songdo Bio Campus in Incheon, South Korea, giving the company a sizable new production base as it tries to become a more consequential player in the global CDMO...

Continue Reading
American Pride Bank Tests a Fast Southeast Expansion

Updated Category News Views 0

Those old Winston-Salem smokestacks make a fitting backdrop for a bank trying to build something new, and American Pride Bank is moving with uncommon speed. Its new office at 450 N. Patterson Ave., Suite 200 sits in the Bailey South building in Innovation Quarter, across from Bailey Park and amid a district deliberately remade for founders, researchers and growing...

Continue Reading
Oracle Takes AI to Construction's Messy Project Middle

Updated Category News Views 141

A stalled drywall inspection can wreck a schedule faster than any glossy AI pitch can repair it. That is the grimy, practical corner Oracle is aiming at with its latest Oracle Primavera Cloud upgrades: the daily hunt for answers, the repeated logging of familiar risks, and the finger-pointing that starts when a milestone is suddenly in danger. This is not a chatbot being...

Continue Reading
Mining's Biodiversity Map Sharpens Location Risks

Updated Category News Views 70

Twelve thousand pins on a map do not settle the mining industry's nature problem, but they do make it much harder to pretend the problem is evenly spread. ICMM's new Global Mining and Metals Biodiversity Dataset overlays 12,000 large-scale formal mining, smelting, refining and processing facilities with ecosystem-condition and conservation indicators. For investors...

Continue Reading
Seeking Alpha Premium Review: Data Meets Human Judgment

Updated Category News Views 115

A spreadsheet can spot a cracked windshield, but it cannot tell you where the truck is headed. That is the useful, slightly irritating truth behind Seeking Alpha Premium’s 2026 pitch: it puts an enormous amount of stock-research machinery in one place, yet the investor still has to do the driving. Software Experts has highlighted the service in its review of...

Continue Reading

Top 5 Most Recently Viewed Articles

US Technology Restrictions: A Temporary Pause Ahead of Talks

Updated Category News Views 251

US Pauses Technology Restrictions on China As crucial diplomatic discussions approach, the US administration has put several significant technology restrictions on hold, affecting China. This suspension comes as a preparation for an important meeting between Donald Trump and Xi Jinping, anticipated to pave the way for enhanced dialogue on trade and technological...

Continue Reading
Vireo Growth Inc. Secures $75 Million Financing for Expansion

Updated Category News Views 347

Vireo Growth Inc. Secures $75 Million Financing for Expansion — $75 million equity financing at $0.625 per Vireo share will result in combined new entity having an industry-leading balance sheet — — Transactions would expand Vireo’s operating footprint to 7 states, 9 cultivation facilities, and 48 dispensaries — — Combined new entity would have an estimated...

Continue Reading
BELFOR Franchise Group Brands Shine on Top Franchise List

Updated Category News Views 290

BELFOR Franchise Group Brands Recognized for Excellence Six distinct brands under the BELFOR Franchise Group umbrella have made the prestigious Franchise Times Top 400 list for 2025. These brands—Chem-Dry, HOODZ, 1-800 WATER DAMAGE, N-Hance, Blue Kangaroo Packoutz, and DUCTZ—stand out for their outstanding national systemwide sales, reflecting the strength and...

Continue Reading
BrainCo Leads BCI Revolution: A Game-Changer Debuts

Updated Category News Views 66

The Frontier of Thought-Controlled Robotics The 2026 World Artificial Intelligence Conference in Shanghai saw BrainCo unleash what felt like a scene straight outta a sci-fi flick. You had a wild display of mind-boggling tech where a person thinks about grabbing a cup, and blam, a robotic arm does it. No joystick, no commands, just pure brainpower in action. This isn't...

Continue Reading
Revolutionizing Data Center Management with AI and Imaging

Updated Category News Views 223

Unleashing Efficiency in Data Center Management In an era where data center operations are continually evolving, the collaboration between AMI and Cupola360 represents a significant leap forward. By merging AMI's Data Center Manager (DCM) with Cupola360's innovative panoramic imaging technology, both companies are setting new standards for efficiency and security in...

Continue Reading